ABMT:OTC-Advanced Biomedical Technologies, Inc (USD)

COMMON STOCK | Medical Devices | OTC

Last Closing Price

USD 0.07

Change

0.00 (0.00)%

Market Cap

USD 4.85M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. It offers polymer osteosynthesis devices, such as surgical screws, binding wires, rods, and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, as well as for reconstructive dental procedures. The company was formerly known as Geostar Mineral Corporation and changed its name to Advanced Biomedical Technologies, Inc. in March 2009. Advanced Biomedical Technologies, Inc. was founded in 2002 and is based in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-25 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SNNUF Smith & Nephew plc

N/A

USD18.82B 41.66 23.50
MCRPF MicroPort Scientific Corporati..

N/A

USD15.15B 219.70 53.08
CHEOY Cochlear Limited

N/A

USD12.39B 51.97 23.12
CHEOF Cochlear Limited

N/A

USD11.94B 45.76 23.12
GGNDF GN Store Nord A/S

N/A

USD11.87B 46.63 3.74
GNNDY GN Store Nord A/S

N/A

USD11.87B 46.40 3.74
MEDGF Medacta Group SA

N/A

USD2.76B 56.57 35.13
NHNKY Nihon Kohden Corporation

N/A

USD2.62B 15.90 0.07
NHNKF Nihon Kohden Corporation

N/A

USD2.11B 24.60 -78.50
DWRKF Drägerwerk AG & Co. KGaA

N/A

USD1.93B 58.71 N/A

ETFs Containing ABMT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -41.67% 13% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -41.67% 13% F 8% F
Trailing 12 Months  
Capital Gain -73.08% 3% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -73.08% 3% F 3% F
Trailing 5 Years  
Capital Gain -53.33% 30% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -53.33% 30% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain 36.78% 47% F 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.78% 47% F 66% D
Risk Return Profile  
Volatility (Standard Deviation) 120.82% 51% F 30% F
Risk Adjusted Return 30.45% 55% F 52% F
Market Capitalization 4.85M 34% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio 7.49 13% F 24% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 15.07% 60% D- 80% B-
Return on Assets -81.76% 32% F 12% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -1.16 95% A 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.